Advances in the Adjunctive Treatment of Lennox-Gastaut Syndrome with Clobazam and Cannabidiol

Jingtian Shi; Chaoyang Chen; Ting Yang; Ran Wei; Xuanling Zhang; Zining Wang; Xiaojuan HU; Ying Zhou

Return

Advances in the Adjunctive Treatment of Lennox-Gastaut Syndrome with Clobazam and Cannabidiol

VernacularTitle:氯巴占与大麻二酚辅助治疗Lennox-Gastaut综合征新进展
Author: Jingtian SHI ¹ ; Chaoyang CHEN ² ; Ting YANG ² ; Ran WEI ² ; Xuanling ZHANG ² ; Zining WANG ² ; Xiaojuan HU ² ; Ying ZHOU ³
Author Information

1. Department of Pharmacy, Peking University First Hospital, Beijing 100034, China，Department of Pharmacy, Peking University First Hospital Ningxia Women and Children′s Hospital, Ningxia Hui Autonomous Region Maternal and Child Health Hospital, Yinchuan 750001, China.
2. Department of Pharmacy, Peking University First Hospital, Beijing 100034, China.
3. Department of Pharmacy, Peking University First Hospital, Beijing 100034, China，Drug Clinical Trial Facility, Peking University First Hospital, Beijing 100034, China.
Publication Type:Review
Keywords: rare diseases; Lennox-Gastaut syndrome; clobazam; cannabidiol; orplan drugs
From: JOURNAL OF RARE DISEASES 2024;3(2):252-259
CountryChina
Language:Chinese
Abstract:
Lennox-Gastaut syndrome (LGS) is a severe, epileptic encephalopathy.In recent years, a variety of drugs have been approved for the treatment of LGS. The U.S. Food and Drug Administration approved clobazam and cannabidiol as adjunctive therapy for LGS in October 2011 and June 2018, respectively. This article provides an overview of clobazam and cannabidiol, including their chemical structures, pharmacological actions, curative effects, safety profile, drug interactions, to introduce the current state of research and the achievements of both drugs.